Adapthealth Corp (AHCO) Q1 2026 Earnings Call Transcript

Why It Matters

The expanded capitated contract creates a recurring, high‑margin revenue engine and bolsters balance‑sheet strength, while credit upgrades and strong free cash flow signal financial resilience despite near‑term cash pressure.

Key Takeaways

• Revenue $3.245B exceeds guidance midpoints
• Adjusted EBITDA $616.7M, 19% margin
• Sleep and respiratory patient censuses hit records
• Diabetes revenue down 7.4% from payer mix shift
• New capitated contract aims for 10M patients

Pulse Analysis

AdaptHealth’s 2025 financial results underscore a rare blend of top‑line resilience and margin expansion in the home‑medical‑equipment (HME) sector. Revenue of $3.245 billion outperformed guidance, while adjusted EBITDA of $616.7 million delivered a 19% margin—figures that compare favorably against peers still grappling with post‑pandemic demand volatility. The GAAP picture was softened by a $128 million goodwill impairment in the Diabetes segment and a $14.5 million legal settlement, yet these non‑cash and one‑off items did not erode the company’s cash‑generating capacity, which produced $219.4 million of free cash flow for the year.

Operationally, AdaptHealth leveraged technology and process redesign to sharpen its service delivery. AI‑driven pilots in sleep order intake and patient scheduling trimmed processing times, while centralizing order intake for sleep and vent products cut average setup from 23 days to nine days. These efficiencies translated into record patient censuses for Sleep Health and Respiratory Health, reinforcing the firm’s competitive moat in a market where speed to serve and adherence rates drive physician referrals and payer contracts. The company’s digital MyApp platform also doubled active users, highlighting a broader shift toward patient‑centric engagement tools.

Strategically, the launch of the industry‑largest capitated contract—targeting up to 10 million patients—positions AdaptHealth for a steady, risk‑adjusted revenue stream that can offset cyclical pressures. Coupled with a $250 million debt reduction, upgraded S&P and Moody’s ratings, and a net leverage ratio of 2.75×, the balance sheet is stronger than at any prior point. Guidance for 2026 anticipates 6‑8% revenue growth and EBITDA of $680‑$730 million, reflecting confidence in the contract’s ramp‑up. While front‑loaded onboarding costs create a short‑term cash‑flow dip, the long‑term upside suggests a durable earnings engine for shareholders and a benchmark for competitors pursuing capitated models.